Acumen Pharmaceuticals Inc
NASDAQ: ABOS · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Acumen Pharmaceuticals Inc (ABOS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | $7.32M | $44.43M | $230.33M | $196.59M | $310.13M | $238.99M | $122.83M |
| Cash & equivalents | $6.55M | $43.78M | $122.16M | $130.10M | $66.89M | $35.63M | $53.99M |
| Current assets | $7.18M | $44.43M | $198.66M | $180.33M | $246.62M | $178.31M | $122.25M |
| Total liabilities | $18.74M | $63.02M | $5.15M | $7.81M | $43.15M | $57.18M | $52.40M |
| Current liabilities | $1.34M | $6.37M | $5.15M | $7.81M | $12.97M | $27.61M | $30.01M |
| Long-term debt | — | — | — | — | $27.34M | $28.45M | $22.40M |
| Shareholder equity | $-11.42M | $-18.59M | $225.18M | $188.78M | $266.97M | $181.82M | $70.43M |
| Retained earnings | $-19.64M | $-26.96M | $-127.57M | $-170.43M | $-222.80M | $-325.13M | $-446.46M |
| Accounts receivable | $30000.00 | $109000.00 | $-83.00 | $-199.00 | $225000.00 | $398000.00 | $625000.00 |
| Inventory | $49000.00 | $91000.00 | $83.00 | $199000.00 | $98000.00 | $159000.00 | — |
| Goodwill | — | — | — | — | — | — | — |
Frequently asked questions
What is Acumen Pharmaceuticals Inc's revenue?
Acumen Pharmaceuticals Inc's trailing twelve-month revenue is $329000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does ABOS generate?
ABOS produced $-115.63M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is ABOS's balance sheet healthy?
ABOS holds $53.99M in cash and equivalents against $22.40M in long-term debt, on $70.43M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.